Pharma loj heev Gilead Sciences (GILD) xa ib tug loj cov nyiaj khwv tau los yeej lub quarter kawg, raws li IBD tau tshaj tawm ua ntej. Nws thim rov qab los ntawm kev poob thaum lig 2021 mus rau qhov nce me me hauv Q1, cuam tshuam cov kws tshuaj ntsuam kwv yees. Xav txog qhov kev sib tw, hnub Thursday Gilead Tshuag Kev txheeb ze zog (RS) Rating nce mus rau 73, nce los ntawm 70 hnub ua ntej. Cov lus nug tam sim no: Nws puas yuav txhim kho lub zog ntawd lossis, nrog rau kev kho kev lag luam loj tam sim no, poob rov qab dua?
X
Gilead Tshuag Tus Nqi Ua Haujlwm nce
Qhov tshiab 73 RS Rating qhia tau hais tias Gilead Tshuag tshaj 73% ntawm tag nrho cov khoom lag luam nyob rau hauv cov nqe lus ntawm Tshuag nqi kev ua tau zoo xyoo dhau los. Kev tshawb fawb kev lag luam qhia tau hais tias cov khoom lag luam mus ua kom tau txais txiaj ntsig loj tshaj plaws feem ntau muaj RS Rating sab qaum teb ntawm 80 thaum lawv pib lawv qhov nce siab tshaj plaws. Saib seb Gilead Sciences tuaj yeem txuas ntxiv rov qab thiab tshem tawm qhov pib.
Ntawm nws lwm qhov kev ntsuas tseem ceeb, Gilead Tshuag muaj 65 Puas Ntsuam Xyuas, muab tso rau saum 35% ntawm cov tuam txhab ntawm ib pawg ntawm tsib qhov kev ntsuas tseem ceeb uas IBD siv. Nws boasts qhov zoo tshaj plaws-ua tau A SMR Kev Ntsuas (muag + cov txiaj ntsig tau nyiaj + rov qab los ntawm kev ncaj ncees), ntawm A rau E nplai nrog A saum. Nws C Kev Sib Nqus / Distribution Rating qhia tau hais tias kwv yees li ntau lub tuam txhab ua lag luam tab tom yuav nws cov khoom muag.
Nrhiav Rau Winning Stocks? Sim No Kev Yoojyim
Gilead Tshuag tab tom sim ua kom tiav kev sib sau ua ke nrog 74.22 muas point. Saib yog tias cov khoom lag luam tuaj yeem tshem tawm tus nqi tawg hauv kev lag luam hnyav. Gilead kaw nrog qhov feem ntau nce hnub Thursday, rau 63.27.
Rebounding Los Ntawm Fluke Quarter?
Gilead Sciences pom ob qho nyiaj khwv tau los thiab kev muag khoom loj hlob nce lub quarter dhau los piv rau lub quarter dhau los. Cov nyiaj tau los ntawm ib feem hauv nws lub quarter tsis ntev los no tau nce 4%, thim rov qab los ntawm 68% poob rau lub quarter dhau los. Kev muag khoom tau nce 3% ntawm ib xyoos dhau ib xyoos rau $ 6.59 nphom, thim rov qab nws 2% poob rau lub sijhawm dhau los. Nws tseem yuav pom tias qhov kawg ntawm 2021 tsis muaj zog yog qhov mob hnyav. Ob peb lub hlis twg ua ntej nws tshaj tawm EPS nce ntawm 68% thiab 26%, ntawm cov nyiaj tau los nce ntawm 21% thiab 13%.
Gilead Tshuag tuav tus lej 37 ntawm nws cov phooj ywg hauv pab pawg kho mob-Biomed / Biotech kev lag luam. Pacira Pharmaceuticals (PCRX) thiab Regeneron Tshuaj (ROV LOS) yog ib pawg ntawm cov khoom lag luam siab tshaj plaws.
Raws li koj sim nrhiav tus cov khoom lag luam zoo tshaj plaws los yuav thiab saib, nyob ze ntawm qhov muag ntawm tus txheeb ze tus nqi zog.
IBD qhov tshwj xeeb RS Rating ntsuas kev ua lag luam kev coj noj coj ua los ntawm kev siv 1 (qhov phem tshaj) rau 99 (zoo tshaj) cov qhab nia uas qhia tias yuav ua li cas cov khoom lag luam tus nqi ua tau zoo nyob rau 52 lub lis piam dhau los tau sib tw tawm tsam tag nrho lwm cov khoom lag luam.
KOJ YUAV TAU LI CAS:
Biotech Thiab Pharmaceutical Industry And Stock News
Cov Khoom Xa Nrog Cov Rho Cov Phooj Ywg Sib Ntxiv Nrog Lub Zog
Vim Li Cas Koj Yuav Siv IBD Qhov Txheeb Ze Tus Zog Txheeb Ze?
Li Cas Cov Kab Mob Sib Zog Yuav Pab Tau Koj Txiav Txim Siab
Saib Yuav Ua Li Cas Thiaj Txo Txoj Kev Pheej Yig, nce paj peev nrog Viav Vias Kev Ua Lag Luam
Tau qhov twg los: https://www.investors.com/news/technology/gilead-sciences-getting-closer-to-key-technical-measure-2/?src=A00220&yptr=yahoo